Aprinoia Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aprinoia Therapeutics, Inc.
Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.
With the global market in sight, several Asian bioventures discussed at BioJapan event recent projects, strategies and challenges in expanding their businesses in APAC. The different characteristics of policies by country and facets of venture capital funding were some of the topics when speakers talked about “what's the ideal collaboration between Asian bioventures?”
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.